Introduction: The infection in pediatric HIV is the reason a lot of problems in Africa The objective of our study were to identify factors associated with mortality during follow-up of children receiving antiretroviral therapy in Togo.
Methods: It was a cross-sectional study of 870 children aged files from 7 weeks to 15 years infected with HIV on antiretroviral treatment, covering the period 1 January 2001 to 31 December 2010 taking in 40 sites medical management in Togo. Data processing was done with the software Epi-Info 6.04d and duplicates were treated by the Software ESOPE.
Results: All patients were infected with HIV-1. In total forty six (46) deaths is 5.29% of the overall cohort were reported in our series. The lethality of the overall cohort followed for 60 months was 5.29%. The survival rate of the overall effective monitoring in our study was 89.2%. Fifty-eight percent (58%) of deaths had affected children in a state of severe malnutrition and forty two percent (42%) in a state of moderate malnutrition. Sixty two percent (62%) of children under HAART treatment died benefited monitoring a psychologist.
Conclusion: The diagnostic inadequacies of pediatric HIV strike the prognosis of infected children. Efforts still needs to be done to improve the load take pediatric HIV in Togo.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Neutralizing antibody immune correlates in COVAIL trial recipients of an mRNA second COVID-19 vaccine boost.
Nat Commun
January 2025
Biostatistics Research Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
Neutralizing antibody titer has been a surrogate endpoint for guiding COVID-19 vaccine approval and use, although the pandemic's evolution and the introduction of variant-adapted vaccine boosters raise questions as to this surrogate's contemporary performance. For 985 recipients of an mRNA second bivalent or monovalent booster containing various Spike inserts [Prototype (Ancestral), Beta, Delta, and/or Omicron BA.1 or BA.
View Article and Find Full Text PDFPrevalence of Anti-HIV Antibodies at 12 Months of Age in Infants Exposed to HIV.
Pediatr Infect Dis J
January 2025
From the Post-Graduation Program in Child and Adolescent Health, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil.
This study determined the prevalence of reactive HIV serology at 12 months of age in infants exposed to HIV in utero. Of the 80 patients analyzed, 50 (63.3%) were anti-HIV reactive.
View Article and Find Full Text PDFUsing creativity and the arts to promote mental health in youth living with HIV in South Africa.
South Afr J HIV Med
December 2024
Department of Psychiatry and Behavioural Sciences, Medical School, University of Minnesota, Minneapolis, United States of America.
Access to adolescent-friendly, culturally relevant and stigma-free mental health support is essential for reducing the long-term psychological, social and economic challenges of mental illness of youth living with HIV (YLWH). Now more than ever, innovative task-shifting interventions, through which non-mental health professionals provide mental health support to YLWH, need to be explored and supported. While many of these have considered shifting tasks to nurses, tapping into the wisdom and inspiration from artists in the community where YLWH are living could represent a novel and potentially powerful task-shifting strategy.
View Article and Find Full Text PDFGerman evidence- and consensus-based guideline on the management of penile urethritis.
J Dtsch Dermatol Ges
January 2025
Department of Infection Epidemiology, Robert Koch Institute, Berlin, Germany.
Urethritis is a common condition predominantly caused by sexually transmitted pathogens such as Chlamydia trachomatis, Neisseria gonorrhoeae, and Mycoplasma genitalium. It is not possible to differentiate with certainty between pathogens on the basis of clinical characteristics alone. However, empirical antibiotic therapy is often initiated in clinical practice.
View Article and Find Full Text PDFSafety, Tolerability, and Pharmacokinetics of Long-Acting Broadly Neutralizing HIV-1 Monoclonal Antibody VRC07523LS in Newborn Infants Exposed to HIV-1.
J Pediatric Infect Dis Soc
January 2025
Vaccine Research Center, National Institute of Allergy and Infectious Diseases, NIH Bethesda, MD, USA.
Background: Vertical HIV-1 transmission despite antiretroviral therapy may be mitigated by use of long-acting, broadly neutralizing, monoclonal antibodies (bNAb) such as VRC07523LS. The present study was designed to determine the safety and pharmacokinetics of VRC07523LS.
Methods: VRC07523LS, 80 mg/dose, was administered subcutaneously after birth to non-breastfed (Cohort 1; N=11, enrolled in USA) and breastfed (Cohort 2; N=11, enrolled in South Africa and Zimbabwe) infants exposed to HIV-1.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!